Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to establishing a sustainable and predictable model for advancing precision genetic medicines. The company highlighted recent progress within its liver-targeted genetic diseases and hematology franchise programs, outlined its strategic priorities for 2026, and noted an extension of its anticipated cash runway. The company's cash, cash equivalents, and marketable securities were valued at approximately $1.25 billion as of the end of 2025. The expected cash runway has been extended into 2029, which is projected to provide substantial support for the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development program. Furthermore, the expansion of the company's liver-targeted genetic diseases franchise is actively underway.